DE69523747D1 - Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen - Google Patents

Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen

Info

Publication number
DE69523747D1
DE69523747D1 DE69523747T DE69523747T DE69523747D1 DE 69523747 D1 DE69523747 D1 DE 69523747D1 DE 69523747 T DE69523747 T DE 69523747T DE 69523747 T DE69523747 T DE 69523747T DE 69523747 D1 DE69523747 D1 DE 69523747D1
Authority
DE
Germany
Prior art keywords
combination
heart failure
mammal
congestive heart
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69523747T
Other languages
English (en)
Other versions
DE69523747T2 (de
Inventor
G Clark
Hongkui Jin
F Paoni
Renhui Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/284,859 external-priority patent/US5661122A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69523747D1 publication Critical patent/DE69523747D1/de
Publication of DE69523747T2 publication Critical patent/DE69523747T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
DE69523747T 1994-04-15 1995-03-30 Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen Expired - Lifetime DE69523747T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22792394A 1994-04-15 1994-04-15
US08/284,859 US5661122A (en) 1994-04-15 1994-08-02 Treatment of congestive heart failure
US08/333,909 US5610134A (en) 1994-04-15 1994-11-03 Treatment of congestive heart failure
PCT/US1995/003755 WO1995028174A1 (en) 1994-04-15 1995-03-30 The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure

Publications (2)

Publication Number Publication Date
DE69523747D1 true DE69523747D1 (de) 2001-12-13
DE69523747T2 DE69523747T2 (de) 2002-08-01

Family

ID=27397790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523747T Expired - Lifetime DE69523747T2 (de) 1994-04-15 1995-03-30 Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen

Country Status (13)

Country Link
US (1) US5610134A (de)
EP (1) EP0755265B1 (de)
JP (1) JP3473623B2 (de)
AT (1) ATE208209T1 (de)
AU (1) AU691273B2 (de)
CA (1) CA2185998C (de)
DE (1) DE69523747T2 (de)
DK (1) DK0755265T3 (de)
ES (1) ES2167427T3 (de)
HK (1) HK1003418A1 (de)
LV (1) LV12966B (de)
PT (1) PT755265E (de)
WO (1) WO1995028174A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3182307B2 (ja) * 1994-12-27 2001-07-03 株式会社荏原製作所 全周流型ポンプ
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) * 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6015384A (en) * 1998-08-31 2000-01-18 Acuson Corporation Ultrasonic system and method for tissue viability imaging
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
PT1196186E (pt) * 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
CZ200260A3 (cs) * 1999-07-12 2002-04-17 Grandis Biotech Gmbh Formulace růstového hormonu
ES2330918T3 (es) 2000-02-11 2009-12-17 Genentech, Inc. Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
FR2805051B1 (fr) * 2000-02-14 2002-12-06 Geophysique Cie Gle Methode de surveillance sismique d'une zone souterraine par utilisation simultanee de plusieurs sources vibrosismiques
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6607517B1 (en) 2001-08-24 2003-08-19 Radiant Medical, Inc. Method of inotropic treatment of heart disease using hypothermia
MXPA05007181A (es) 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Cristales de la hormona de crecimiento humano y metodos para prepararlos.
EP1841443A4 (de) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc Verfahren und system zur behandlung von herzfehlern
AU2008323719B2 (en) 2007-11-09 2013-04-04 New York Medical College Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
EP2225362A1 (de) 2007-11-30 2010-09-08 New York Medical College Verfahren zur verminderung von transplantatabstossung und herz-allotransplantat-vaskulopathie mittels implantieren autologer stammzellen
AU2008334058B2 (en) 2007-11-30 2014-07-10 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
EP0554381B2 (de) * 1990-10-25 2000-04-26 Genentech, Inc. Verwendung gegen reaktive sauerstoffverbindungen schützender wirkstoffe
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
WO1995028174A1 (en) 1995-10-26
CA2185998A1 (en) 1995-10-26
ES2167427T3 (es) 2002-05-16
ATE208209T1 (de) 2001-11-15
JP3473623B2 (ja) 2003-12-08
CA2185998C (en) 2011-02-22
AU691273B2 (en) 1998-05-14
AU2195695A (en) 1995-11-10
EP0755265B1 (de) 2001-11-07
PT755265E (pt) 2002-04-29
US5610134A (en) 1997-03-11
DE69523747T2 (de) 2002-08-01
HK1003418A1 (en) 1998-10-30
JPH09512008A (ja) 1997-12-02
LV12966B (en) 2003-05-20
DK0755265T3 (da) 2002-03-04
EP0755265A1 (de) 1997-01-29

Similar Documents

Publication Publication Date Title
DE69523747D1 (de) Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69617469T2 (de) Behandlung von multipler sklerose
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
ATE264676T1 (de) Verwendung von dha in der behandlung von dyslexie
ATE218330T1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE215835T1 (de) Verfahren zur systemischen behandlung katabolischer zustände und systemischer gewebeschädigung
DE69018799T2 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69808131D1 (de) Verfahren zur vorbeugung und behandlung des myokardialen stunnings
ATE228006T1 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
MX9604803A (es) Combinacion de hormona del crecimiento y factor de crecimiento similar a insulina para el tratamiento del fallo cardiaco congestivo.
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE58456T1 (de) Zusammensetzung zur behandlung von laeuseplagen.
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
DE50009220D1 (de) Verwendung von moxonidin zur behandlung nach herzinfarkt
UA23098A (uk) Спосіб приготуваhhя морфологічhих препаратів для імуhоцитохімічhого досліджеhhя
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition